HeartSciences posts $3.2M FQ1 2027 net loss; no meaningful revenue
HeartSciences reported a $3.2 million net loss for its fiscal first quarter ended July 31, 2026, with no meaningful revenue. Loss from operations was $2.9 million, including a $0.3 million inventory reserve tied to its wavECG device.
HeartSciences reported a net loss of $3.2 million for the fiscal first quarter ended July 31, 2026, and said it generated no meaningful revenue in the period. Loss from operations was $2.9 million, and the company booked a $0.3 million inventory reserve related to its wavECG device. As of July 31, 2026, HeartSciences…